PULM (Pulmatrix) Days Payable: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PULM Pulmatrix Inc PULM
30 GF Score
Price $1.57
! 1 Warning Sign
View Full Analysis

What is Pulmatrix Days Payable?

Pulmatrix PULM 30 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates PULM with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 701 Biotechnology companies, Pulmatrix ranks worse than 142653.21% on this metric.

Pulmatrix's average Accounts Payable for the three months ended in Mar. 2026 was $0.46 Mil. Pulmatrix's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Pulmatrix's Days Payable or its related term are showing as below:

PULM's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84
* Ranked among companies with meaningful Days Payable only.

Pulmatrix's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Pulmatrix Days Payable Historical Data

* Premium members only.

The historical data trend for Pulmatrix's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmatrix Days Payable Chart

Pulmatrix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pulmatrix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PULM vs CDIO, NXTC, BCAB: Days Payable Comparison

For the Biotechnology subindustry, Pulmatrix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulmatrix Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulmatrix's Days Payable distribution charts can be found below:

* The bar in red indicates where Pulmatrix's Days Payable falls into.


PULM
30GF Score
Pulmatrix Inc PULM
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulmatrix Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Pulmatrix's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (0.809 + 0.272) / 2 ) / 0*365
=0.5405 / 0*365
=N/A

Pulmatrix's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (0.272 + 0.651) / 2 ) / 0*365 / 4
=0.4615 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Pulmatrix (PULM) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pulmatrix and its competitors. According to the industry distribution chart, Pulmatrix ranks #999999 out of 701 companies in the Biotechnology industry.
Is Pulmatrix's Days Payable too high?
Pulmatrix's current Days Payable is 0.00. Based on the distribution chart, Pulmatrix ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pulmatrix has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Pulmatrix's Days Payable compare to CDIO and NXTC?
According to the Biotechnology industry distribution chart, Pulmatrix ranks #999999 out of 701 companies for Days Payable. This places Pulmatrix in the lower half of its industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pulmatrix and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulmatrix's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmatrix stock overvalued right now?
Pulmatrix (PULM) has a current Days Payable of 0.00. The current Days Payable is 0.00. Pulmatrix's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pulmatrix (PULM), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pulmatrix Business Description

Other Exchanges 2PU:Germany
Address 945 Concord Street, Suite 1217, Framingham, MA, USA, 01701
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
30GF Score

Get the complete analysis for PULM

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price